What Researchers Did
Researchers reported on a case of a 42-year-old woman with refractory pyoderma gangrenosum treated with hyperbaric oxygen therapy after conventional treatments failed.
What They Found
After a 42-year-old woman's pyoderma gangrenosum remained unresponsive to conventional treatments, including infliximab for 12 weeks and adalimumab, hyperbaric oxygen therapy was initiated. This salvage treatment led to a positive resolution of her refractory pyoderma gangrenosum.
What This Means for Canadian Patients
For Canadian patients with pyoderma gangrenosum that does not respond to conventional treatments, hyperbaric oxygen therapy may offer a potential salvage treatment option. This approach could be considered when other therapies have failed to achieve wound healing.
Canadian Relevance
This study has no direct Canadian connection as it was conducted outside of Canada.
Study Limitations
As a single case report, the findings of this study cannot be generalized to a broader patient population.